We provide healthcare professionals with a comprehensive portfolio of clinically-proven wound care therapies — from autologous blood-derived treatments to omega fatty acid matrices and human tissue allografts.
Each product addresses different mechanisms of wound healing, giving clinicians the flexibility to match therapy to patient needs.
A personalized, point-of-care wound management system created from the patient's own whole blood. The blood clot serves as a protective covering and optimizes the body's natural healing potential.
A first-in-class, 510(k) cleared combination drug/device with multimodal mechanisms of action. This omega fatty acid-based anhydrous solid matrix delivers complete, personalized therapy for all phases of wound healing.
A sterile, dehydrated human amnion/chorion membrane allograft derived from placental tissue. Retains structural properties and key growth factors to provide a protective matrix for wound healing.
Our products cover a comprehensive range of chronic, surgical, and traumatic wound types.
Our products are supported by peer-reviewed research, clinical trials, and real-world clinical outcomes.
ActiGraftPRO demonstrated 173% more patients healed vs. standard of care in a randomized controlled trial for diabetic foot ulcers.
OCM™ achieved 77% wound closure across multiple wound types with a mean healing time of 6.5 weeks in real-world clinical use.
60% wound area reduction in 4 weeks across multiple wound types with the OCM™ comprehensive treatment protocol.
No potential allergenicity, no sensitization, and no known product-related adverse events in safety testing of the OCM™ formulation.
We equip healthcare professionals with the therapies, clinical resources, and dedicated support needed to improve patient outcomes.
Products backed by FDA clearance and rigorous quality standards you and your patients can trust.
Hands-on clinical training, product education, and ongoing support to help your team get the most out of every therapy.
Three distinct mechanisms of action — autologous, synthetic matrix, and allograft — to match therapy to each patient's needs.
Peer-reviewed publications, randomized controlled trials, and extensive real-world case studies.
Point-of-care solutions with ambient storage. No waiting periods — start treating wounds on day one.
Options for patients with religious constraints, cultural sensitivities, blood thinners, and complex comorbidities.
Whether you're a clinician, facility administrator, or distributor, we'd love to hear from you.
Reach out to learn more about our products, request samples, schedule a demo, or explore partnership opportunities. Our team is here to support you.
ActiGraftPRO by RedDress
OCM™ by Omeza / Advanced Solution
AmchoMatrix by Cellution Biologics